medigraphic.com

2002, Number 2

<< Back Next >>

Rev Med Hosp Gen Mex 2002; 65 (2)

Prophylactic treatment in migraine with valproato of magnesium and their relation with the plasmatic levels

Ramos-Ramírez R, López-Ruiz M, Pérez-Montoya E, Ramírez-Sanjuan E

Language: Spanish
References: 44
Page: 75-82
PDF size: 121.84 Kb.


ABSTRACT

We were carried out a clinical study to evaluate the effectiveness and therapeutic security of the valproato of magnesium in the migraine prophylaxis and their relationship with the plasmatic levels using two dosage outlines 600 and 1,200 mg of valproato of magnesium in pills of prolonged liberation during 56 days. Nineteen patients were studied divided in two groups, (group I = 9, group II = 10). Plasmatic level of valproato was determined of the 8 at the 14 days of treatment. The frequency of migraine attacks per month in the group I, diminished from 8 to 2 (p = 0.008, T of Wilcoxon), the group II of 5 at 2 (p = 0.004, T of Wilcoxon). The duration of the pain in the group II diminished from 20 to 12 h (p ‹ 0.05, T of Wilcoxon). The levels plasmatic average of the Valproato were of 38 µg/mL in the group I and of 70 µg/mL in the group II. The adverse effects were epigastralgia, dizziness, vomit, fall of the hair and increment of weight. The valproato of magnesium reduced the frequency of the pain crisis significantly in both groups, the duration of the pain diminished significantly in the group II. The plasmatic levels of valproato in the group I, went smaller to those considered as therapeutic in epilepsy.


REFERENCES

  1. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia’s and facial pain. Cephalalgia 1988; 8 (suppl 7): 1- 96.

  2. Silberstein SD, Lipton R, Solomon S. Classification of daily and near daily Headache: Proposed revisions to the IHS Classification. Headache 1994; 34: 1-7.

  3. Schulman EA, Silberstein SD. Symptomatic and prophylactic treatment of migraine and tension type headache. Neurology 1992; 42 (suppl 3): 16-21.

  4. Silberstein SD. Recapitulation diagnostic treatment of migraine. Neurology 1994; 44: S6-S16.

  5. Olesen JA. A review et current drugs for migraine. J Neurol 1991; 238: S23-S27.

  6. Solomon GD. Therapeutic advances in migraine. J Clin Pharmacol 1993; 33: 200-209.

  7. Sorensen KV. Valproate: A new drug in migraine prophylaxis. Acta Neurol Scand 1988; 78: 346-348.

  8. Dávila PJ. Efecto profiláctico del valproato de magnesio en la migraña con y sin aura. Tesis Profesional para graduarse como neurólogo. 1995.

  9. Kupferberg JH. Gas-liquid chromatographic quantitation of valproic acid. In: Pipenger JK, Penry H. Kutt(eds). Antiepileptic drugs CE. Quantitative analysis and interpretation. New York, USA: Raven Press, 1978: 147-151.

  10. Sicuteri F. Headache biochemistry and pharmacology. Arch Neurobiol 1974; 57: 27-31.

  11. Moskowits MA, Cutrer FH. Sumatriptan: A receptors-targeted ford migraine. Ann Rev Med 1993; 44: 145-154.

  12. Galtai V, Sarchielli P, Floridi A. Vasoactive peptides levels in the plasma of young migraine patients white and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-390.

  13. Nishikawa T, Scatton B. Inhibitory influence of Gaba on central serotoninergic transmission: Raphe nuclei as the neuroanatomical site of the GABAergic inhibition of cerebral serotoninergic neurons. Brain Res 1985; 248: 257-267.

  14. Goadsby PJ, Zagani AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1999; 31: 365-361.

  15. Goasby PJ. The pharmacology of headache. Progr Neurobiol 2000; 62: 509 -525.

  16. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology 1972; 22: 366-369.

  17. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. BMJ 1974; 2: 699-701.

  18. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol a comparison with placebo. Cephalalgia 1987; 7 (suppl 6): 464.

  19. Amery WK. Flunarizine, a calcium channel blocker; a new prophylactic drug in migraine. Headache 1983; 23: 70-74.

  20. Louis PA. Double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981; 21: 235-239.

  21. Mathew NT. Valproate in the treatment of persistent chronic daily headache. Headache 1990; 30: 301.

  22. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study vs placebo. Cephalalgia 1992; 12: 81-84.

  23. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo controlled, and crossover study. Neurology 1994; 44: 647-651.

  24. Silberstein SD, Saper J, Matew N. The safety and efficacy of valproex sodium in the prophylaxis of migraine headache: a multicenter, double-blind, placebo-controlled trial. Headache 1993; 33: 264-265.

  25. Sianard-Gainko J, Leanearts M, Bastings E, Sodium valproate in severe migraine and tension-type headache: clinical efficacy and correlations with blood levels. Cephalalgia 1993; 13: 252- 254.

  26. Johannessen PJ. Mechanisms of action of valproate a commentatory. Neurochem Internat 2000; 37: 103-110.

  27. Ferrari MD, Odnik J, Bos KD. Neuroexcitatory plasma aminoacids are elevated in migraine. Neurology 1990; 40: 1582-1586.

  28. Welsh KMD, D’Andrea G, Tepley N, Barkly G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1989; 8 (4): 817-828.

  29. Mc Donald RL. Mechanisms of anticonvulsivant drug action. In: Pedley, Meldrum BS. Recent advances in epilepsy. I. Edinburgh: Churchill Livingstone, 1983; 1-23.

  30. Galtai V, Sarchielli P, Coat G, Firenco A., Morucci P, Abbritti G. Serum and salivary magnesium levels in migraine. Headache 1992; 32: 132-135.

  31. Galtai V, Sarchielli P, Abbritti G, Morucci P. Red blood cell magnesium levels in migraine patients. Cephalalgia 1993; 13: 94-99.

  32. Lazko JA, Chang T, Daftsios AC, Eiseman I, Smith CT, Buchanan AR. Bioavailability of calcium valproate in normal men compared with free acid and sodium salt. Ther Drug Monit 1973; 35: 409 - 417.

  33. Balbi A, Sottofattori E, Mazzei M, Sannita GW. Study of bioequivalence of magnesium and sodium valproates. J Pharmaceut Biomed Analysis 1991; 9 (4): 317-321.

  34. Matera M, Caruso G, Gilotta GMS, Raffaele R. Antiepileptic efficacy of valproic acid. Clinical, electroencephalographic and neuropsychological comparison of the effects of magnesium and sodium salts. Curret Therap Res 1990; 48 (2): 356-368.

  35. Onofrj M, Colangelo U, Malatesta G, Di Giovanni M. Studio comparativo di preparazioni di valproato (VPA) di sodio e di magnesio nel trattamento di pazienti affeti da crisi epilepttiche: Revista di Neurología 1998; 58 (6): 224-230.

  36. Biondi R, Bella R, Magro E, Marziolo R, Leocata R, Pennisi G. Valproato di magnesio e connotación psihico-compartamentali in soggetti con epilessia medio grave. Boll Leg It Epil 1989; 66/67: 329-331.

  37. Mazza S. Di Trapini G, Petrella AM, Mennuni G, Azzoni A. Eficacia clinica del Valproato di magnesio nel trattamento delle epilepssie parziali e generalízate. Boll Leg It 1990; 70/71: 373-375.

  38. Canger R, Guidolin L. Clinical efficacy and tolerability of magnesium valproate as monotherapy in patients with generalized or partial epilepsy. Clin Drug Invest 2000; 20 (4) 215-221.

  39. Eadie MJ, Tyrer JH, Smith GA, Mc Kauge L. Pharmacokinetics of drugs used for petit mal absence epilepsy. Clin Ex Ptl Neurol 1977; 14: 172-183.

  40. Wulff K, Flachs H, Wurtz-Jorgensen A, Gram L. Clinical pharmacological aspects of valproate sodium. Epilepsia (Amst) 1971; 18: 149-157.

  41. Bialer M, Friedman M, Dubrovsky J. Relation between absorption half-life values of four novel sustained-release dosage form of valproic acid dogs and human. Biopharm Drug Disposition 1986; 7: 495-500.

  42. Roberts D, Easter D, O’Bryan-Tear G. Epilium® Chrono: A multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Disposition 1996; 17: 175-182.

  43. Retzow A, Vens-Capell B, Wangemann M. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. Arzneim-Forsch/Drug Res 1997; 47: 1347-1350.

  44. Rabasseda X. Valproato de magnesio antiepiléptico de amplio espectro: Drugs of Today 1994; 30: 3-22.




2020     |     www.medigraphic.com